WO2013037736A1 - 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant - Google Patents

4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant Download PDF

Info

Publication number
WO2013037736A1
WO2013037736A1 PCT/EP2012/067654 EP2012067654W WO2013037736A1 WO 2013037736 A1 WO2013037736 A1 WO 2013037736A1 EP 2012067654 W EP2012067654 W EP 2012067654W WO 2013037736 A1 WO2013037736 A1 WO 2013037736A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
pyrazolo
tetrahydro
indan
pyridin
Prior art date
Application number
PCT/EP2012/067654
Other languages
English (en)
Inventor
Laurent Bialy
Josef Pernerstorfer
Klaus Wirth
Klaus Steinmeyer
Gerhard Hessler
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Priority to MX2014002968A priority Critical patent/MX2014002968A/es
Priority to BR112014005583A priority patent/BR112014005583A2/pt
Priority to EA201490621A priority patent/EA023648B1/ru
Publication of WO2013037736A1 publication Critical patent/WO2013037736A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • the invention relates to 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine compounds of the formula I,
  • the compounds of formula I act on the TASK-1 (KCNK3) potassium channel.
  • the compounds are suitable for the treatment of several pathologies and are suitable as antiarrhythmic active ingredients, for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
  • AF atrial fibrillation
  • atrial flutter for example atrial fibrillation (AF) or atrial flutter.
  • K 2 p channels are widespread membrane proteins which, owing to their influences on cell membrane potentials, play an important role in many physiological processes.
  • the group of the potassium channels with four transmembrane segments is delimited from the two others in that their representatives each have two pore domains, which is why these channels are also referred to as K 2 p channels (Coetzee W.J. et al; Molecular diversity of K+ channels; Ann. New York Acad. Sci. 1999 (868), 233-285).
  • K 2 p channels are characterized in that the "leak” or "background” currents flow through them, which play an important role for the resting membrane potential and hence the excitability of nerve or muscle cells.
  • a family which is of particular interest among the K 2 p channels is that of the TASK channels (tandem of P domains in a weak inwardly rectifying K + channel, [TWIK]- related acid-sensitive K + channels), which include TASK-1 , TASK-3, and TASK-5 subtype (D.A. Bayliss, P. Barrett, Trends in Pharmacological Sciences, 2008, 29(1 1 ), 566-575).
  • Other terms used in the literature for the underlying genes are KCNK3 or K2P3.1 (TASK-1 ), KCNK9 or K2P9.1 (TASK-3) and KCNK15 or K2P15.1 (TASK-5).
  • the greatest homology within this family is possessed by the TASK-1 and TASK-3 channels with an amino acid identity of more than 50%. Dimerization of K 2 p channels forms functional potassium channels with a total of four pore units. The streams which flow through these channels are referred to in the literature as IKso stream.
  • IKso stream The streams which flow through these channels.
  • heterodimerization of TASK-1 and TASK-3 is also possible in this context (Berg A.P., Talley E.M., Manger J.
  • Motoneurons express Heteromeric TWIK- related acid-sensitive K+ (TASK) Channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits; J. Neuroscience 2004 (24), 6693 - 6702).
  • the TASK channels are notable in particular for their very strong dependence upon the extracellular pH in the physiological range (pK ca. 6,5-7,5).
  • the channels are inhibited at acidic pH and activated at alkaline pH. Owing to this pH dependence, the physiological function of a sensor which translates small changes in the extracellular pH to corresponding cellular signals is ascribed to the TASK channels (Duprat F., Lesage F., Fink M., Reyes R., Heurteaux C, Lazdunski M.; TASK, a human background K+ channel to sense external pH variations near physiological pH;
  • TASK-1 knock-out mice show a mild phenotype and have been described and appear generally in good health and show normal breeding behavior (Journal of Neuroscience (2005), 25(49), 1 1455-1 1467).
  • TASK-1 is expressed in the brain and also in spinal ganglia and some peripheral tissues, for example pancreas, placenta, uterus, lung, heart, kidney, small intestine and stomach.
  • TASK-1 has been detected in the chemosensitive cells of the brainstem and of the carotid bodies, and also the motor neurons of the
  • hypoglossal nerve Medhurst A.D., Rennie G., Chapman C.G., Meadows H.,
  • TASK-1 potassium channels have been detected in motor neurons of the hypoglossal nerve, a motor cranial nerve which possesses the most important function for the maintenance and patency of the upper respiratory pathways, and locus coeruleus. It has been found that TASK-1 channels are involved in respiratory regulation in respiratory neurons of the brainstem, in carotid bodies and in motor neurons of the hypoglossal nerve, and also in
  • TASK-1 is a highly modulated pH-sensitive 'leak' K+ channel expressed in brainstem respiratory neurons; Respiration Physiology 2001 (129), 159 - 174).
  • An increase in the activity of chemosensitive neurons in conjunction with an activation of the motor neurons of the hypoglossal nerve through blockage of the TASK-1 channel can stimulate respiration and simultaneously stabilize the upper airways to protect them from collapse and occlusion. Moreover, snoring can be inhibited by stabilizing the upper airway via an increase in pharyngeal muscle activity.
  • the blockage of the TASK-1 ion channels is therefore useful in the treatment of respiratory disorders, for example of sleep apnea (Brendel, J.; Goegelein, H.; Wirth, K.; Kamm, W., WO2007124849).
  • TASK-1 channels are responsible for programmed cell death (apoptosis) in granulosa cells, and that the cell death can be prevented by blocking the TASK-3.
  • TASK-1 is relevant for setting the resting membrane potential and balancing neuronal excitability that is expressed on T cells and neurons, and is a key modulator of T cell immunity and neurodegeneration in autoimmune central nervous system inflammation.
  • TASK1 (-/-) mice showed a significantly reduced clinical severity and markedly reduced axonal degeneration compared with wild-type controls.
  • T cells from TASK1 (-/-) mice displayed impaired T cell proliferation and cytokine production, while the immune repertoire is otherwise normal.
  • TASK1 exhibits an independent neuroprotective effect which was demonstrated using both a model of acutely prepared brain slices cocultured with activated T cells as well as in vitro cultivation experiments with isolated optic nerves.
  • TASK-1 blockers are potent compounds useful for the therapy of inflammatory and degenerative central nervous system disorders (Bittner Stefan; Meuth Sven G; Gobel Kerstin; Melzer Nico; Herrmann Alexander M; Simon Ole J; Weisberger Andreas; Budde Thomas; Bayliss Douglas A; Bendszus Martin; Wiendl Heinz , Brain : a journal of neurology (2009), 132(Pt 9), 2501 -16).
  • TASK-1 a member of two-pore-domain (K2P) potassium channel family, has emerged as a target for the pharmacological treatment of atrial fibrillation recently.
  • Two-pore-domain (K2P) potassium channels mediate background potassium currents, stabilizing resting membrane potential and expediting action potential repolarization.
  • TASK-1 channels have been shown to play a role in cardiac repolarization, (Basic Res Cardiol. 201 1 Jan;106(1 ):75-87, Putzke C, Wemhoner K, Sachse FB, Rinne S, Schlichthorl G, Li XT, Jae L, Eckhardt I,
  • Atrial fibrillation (AF) and atrial flutter are extremely common cardiac rhythm disorder that causes substantial morbidity and contributes to mortality (Journal of Clinical Invest. 201 1 ;121 (8):2955-2968).
  • Presently available therapeutic approaches have major limitations, including limited efficacy and potentially serious side effects such as malignant ventricular arrhythmia induction or negative inotropic effects. The occurrence of AF increases with age and frequently leads to fatal sequelae such as stroke.
  • the class I and III antiarrhythmics in use at present reduce the rate of recurrence of AF but are used to only a limited extent because of their potential proarrhythmic side effects and limited efficacy.
  • the growing incidence of AF emphasizes the importance of identifying appropriate treatments, particularly drugs, that are safe, effective, and associated with improved clinical outcomes.
  • the length of the action potential is essentially determined by the extent of repolarizing K + currents which flow out of the cells through various K + channels.
  • TASK-1 constitutes one of those repolarizing potassium currents. Its inhibition prolong the action potential and thereby refractoriness.
  • the therapeutic efficacy of the ⁇ blockers has been found to decline under the conditions of tachycardia (electrical tachycardic atrial remodelling).
  • TASK-1 expression in the human heart has been shown to be restricted to the atria with no or very little expression in the ventricles.
  • a further advantage is that TASK-1 expression is not decreased but even slightly increased in atrial fibrillation patients compared with sinus rhythm patients, by contrast a decreased expression of other atrial K + channels has been reported in atrial fibrillation patients compared with sinus rhythm patients: see for example Basic. Res. Cardiol. 2003, 98, 137-148; Brundel B.J.J. M. et al., JACC 2001 , 37, 926-932).
  • TASK-1 is still expressed in the target patient population (Journal of Molecular Medicine 2004, 308-316; European Journal of Physiology 2005, 450, 201 -208, WO 2005/016965; Ellinghaus P. et al., J. Thoracic Cardiovascular Surgery 2005, 129, 1383-1390).
  • TASK channels only very few pharmacological modulators of these channels are known to date in the literature.
  • an activation of the TASK-1 channel can be achieved by therapeutic concentrations of the inhalative anesthetics halothane and isoflurane (Patel A.J., Honore E., Lesage F., Fink M., Romey G., Lazdunski M.; Inhalational anesthetics activate two-pore-domain background K+ channels; Nature Neurosci. 1999 (2), 422-426).
  • Kv1 .5 blockers which also inhibit the TASK-1 channel are described in the state of the art (Brendel, J.; Goegelein, H.; Wirth, K.; Kamm, W., WO2007124849, Brendel, J.; Englert, H. C; Wirth, K.; Wagner, M.;
  • a Specific Two-pore Domain Potassium Channel Blocker Defines the Structure of the TASK-1 Open Pore; Journal of Biological Chemistry (201 1 ), 286(16), 13977-13984). Also arachidonamide anandamide (an endogenous ligand of the cannabinoid receptor) and its methanandamide homolog have been described as TASK-1 blockers (Maingret F., Patel A.J., Lazdunski M., Honore E.; The
  • endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1 ; EMBO J. 2001 (20), 47-54).
  • Doxapram which is used for the treatment of respiratory disorders has been stated to be a TASK-1 blocker (Cotten J.F., Keshavaprasad B., Laster M.J., Eger E.I., Yost C.S.; The Ventilatory Stimulant Doxapram Inhibits TASK Tandem Pore (K 2 p) Potassium Channel Function but Does Not Affect Minimum Alveolar Anesthetic Concentration; Anesth. Analg. 2006 (102) 779-785).
  • a goal of the present invention is to provide efficient TASK-1 inhibitors suitable for the treatment and prevention of TASK-1 related conditions.
  • the present invention relates to TASK-1 blockers of the formula I wherein
  • aryl and heteroaryl are optionally substituted with 1 -3 substituents selected independently from F, CI, Br, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy-, (Ci- C 6 )-alkyl-S-, NC-, (Ci-C 6 )-alkyl-OC(O)-, (Ci-C 6 )-alkyl-SO 2 -, (Ci-C 6 )- alkyloxy-(Ci-C 6 )-alkyl- or R 12 R 13 N-C(O)-,
  • R2 H OH, (Ci-C 6 )-alkyl, (Ci-C 6 )-alkyloxy-, (Ci-C 6 )-alkyl-C(0)0-;
  • R3 H (Ci-C 6 )-alkyl;
  • R4 H F, (Ci-C6)-alkyl, wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine;
  • R6 to R9 are each independently selected from H, F, CI, Br, NC-, (Ci-C6)-alkyl, (C3- C 6 )-cycloalkyl, (Ci-C 6 )-alkyl-SO 2 -, (d-C 6 )-alkyl-OC(O)-, (Ci-C 6 )-alkyloxy-, (d-
  • R10 H, (Ci-C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (Ci-C 6 )-alkyloxy-, (Ci-C 6 )-alkyl-S-, HO-(d- C 6 )-alkyl-, (Ci-C 6 )-alkyl-O-(Ci-C 6 )-alkyl-, (C 3 -C 6 )-cycloalkyl-(Ci-C 6 )-alkyl- or R 12 R 13 N-,
  • R1 1 H, (C 3 -C 6 )-cycloalkyl, OH, (Ci-C 6 )-alkyloxy- or (Ci-C 6 )-alkyl-S-,
  • R12 and R13 are each independently H or (Ci-C 6 )-alkyl
  • A phenyl, furanyl, furazanyl, imidazolyl, isothiazolyl, isoxazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,2.5-oxadiazolyl, 1 ,3,4-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, 1 ,2,3- thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,2.5-thiadiazolyl, 1 ,3,4-thiadiazolyl, thiazolyl, thiophenyl, triazinyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,2.5-triazolyl, or 1 ,3,4- triazolyl
  • R1 R 10 -C(O)-, R 11 -(Ci-C 4 )-alkyl, (C 3 -C 6 )-cycloalkyl, or (Ci-C 2 )-alkyl-SO 2 -;
  • R2 H, OH, (Ci-C 4 )-alkyloxy- or (Ci-C 4 )-alkyl-C(O)O-;
  • R3 H, (Ci-C 6 )-alkyl
  • R4 H, F, (Ci-C6)-alkyl, wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine;
  • R5 H, F, (Ci-C6)-alkyl, wherein one or more hydrogen atoms of the alkyl residue may be replaced by fluorine;
  • R6 to R9 are each independently selected from H, F, CI, Br, NC-, (Ci-C 4 )-alkyl,
  • R10 (Ci-C 4 )-alkyl, cyclopropyl, (Ci-C 4 )-alkyloxy-, (Ci-C 4 )-alkyl-S-, HO-(Ci-C 4 )-alkyl-
  • R1 1 H, cyclopropyl, OH, (Ci-C 4 )-alkyloxy-, (Ci-C 4 )-alkyl-S-,
  • R12 and R13 are each independently H or (Ci-C 4 )-alkyl
  • A phenyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyrazolyl, imidazolyl, isothiazolyl, thiazolyl, or thiophenyl radicals,
  • R1 R 10 -C(O)-, R 11 -(Ci-C 4 )-alkyl- or CH 3 -SO 2 -;
  • R2 OH, methoxy, ethoxy, methyl-C(O)O-, ethyl-C(O)O-;
  • R6 to R9 are each independently selected from H, F, CI, Br, NC-, methyl, ethyl,
  • R10 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
  • R1 1 H, cyclopropyl, methoxy, ethoxy, CF 3 ;
  • R12 and R13 are each independently H, methyl or ethyl
  • A phenyl, pyridyl, isothiazolyl, thiazolyl, or thiophenyl radicals
  • R1 R 10 -C(O)-, R 11 -(C n H 2n )-, isopropyl, tert-butyl or CH 3 -SO 2 -,
  • n 1 , 2 or 3;
  • R2 OH, methoxy
  • R3 H, methyl
  • R4, R5, R6 H
  • R7, R8 are independently selected from H, F, CI, Br;
  • R9 H, F, CI, Br, NC-, methyl, ethyl, cyclopropyl, methoxy, ethoxy, methyl-S-, ethyls' or CF 3 ;
  • R10 methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl,
  • R1 1 H, cyclopropyl, methoxy, CF 3 ;
  • a further embodiment describes compounds of the formula I in which A is phenyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, 2-thiophenyl, 3-thiophenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 2- imidazolyl, 4-imidazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4- isothiazolyl, 5-isothiazolyl, where each of the aryl radicals, for example phenyl, is unsubstituted or substituted with 1 , 2 or 3 residues selected independently from F,
  • Alkyl radicals have between 1 and 6, for example between 1 and 4 carbon atoms and may be straight-chain or branched. Alkyl radicals may also be straight-chain or branched if they are substituted or are present in other radicals, for example in an alkyloxy radical (alkoxy radical) or in a fluorinated alkyl radical. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert- butyl. One or more, for example 1 , 2, 3, 4, 5, 6, 7, 8, or 9 hydrogen atoms in alkyl radicals may be replaced by fluorine atoms.
  • fluorinated alkyl radicals are CF 3 , CF 2 H and CFH 2 .
  • Substituted alkyl radicals may be substituted in any positions.
  • alkyloxy radicals are methoxy and ethoxy.
  • alkyl radicals which in the definition of a group in the compounds of the formula I are bonded to two adjacent groups, or linked to two groups, and may be regarded as divalent alkyl radicals (alkanediyl radicals, alkylene radicals), like in the case of the alkyl part of a substituted alkyl group, for example the group (Ci-C6)-alkyloxy-(CrC6)-alkyl- or the group R 1 1 -(Ci-Ce)- alkyl-, in which groups and likewise in other groups the terminal hyphen denotes the free bond via which the group is bonded, and thus indicates via which subgroup a group composed of subgroups is bonded.
  • alkyl radicals which in the definition of a group in the compounds of the formula I are bonded to two adjacent groups, or linked to two groups, and may be regarded as divalent alkyl radicals (alkanediyl radicals, alkylene radicals), like in the case of the alkyl part
  • radicals can also be straight- chain or branched, the bonds to the adjacent groups can be located in any positions and can start from the same carbon atom or from different carbon atoms, and they can be unsubstituted or substituted by fluorine substituents independently of any other substituents.
  • divalent alkyl radicals are methylene, 1 ,1 - ethylene, 1 ,2-ethylene, 1 ,1 -propylene, 1 ,2-propylene, 2,2-propylene, 1 ,3-propylene, 1 ,1 -butylene, 1 ,4-butylene, etc.
  • cycloalkyl radicals having 3 to 6 C atoms are cyclopropyl, cyclobutyl, 1 - methylcyclopropyl-, 2-methylcyclopropyl-, cyclobutyl, 2-methylcyclobutyl-, 3- methylcyclobutyl-, cyclopentyl, 2-methylcyclopentyl-, 3-methylcyclopentyl-, cyclohexyl etc.
  • heteroaryl residues are five or six-membered rings, comprising 1 to 3 heteroatoms selected from the group N, O and S, wherein a heteroaryl ring in one embodiment comprises only one O or S atom.
  • heteroaryl groups are 2-thiophenyl, 3-thiophenyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2- pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazolyl, 4-pyrazolyl, 2-imidazolyl, 4- imidazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5- isothiazolyl, wherein in one embodiment the heteroaryl groups are 2-pyridyl, 3-pyridyl and 4-pyridyl.
  • heteroaryl residues may unsubstituted or substituted with one or two substituents.
  • substituents of the heteroaryl residues are F, CI, methoxy, ethoxy, methyl, ethyl, NC-, CF 3 O-, CF 3 .
  • an aryl residue is phenyl, wherein one or two hydrogen may be replaced by substituents, for example selected from the group F, CI, methoxy, ethoxy, methyl, ethyl, NC-, CF 3 O-, CF 3 . If a radical is disubstituted or trisubstituted, the substituents may be identical or different.
  • the invention also includes the corresponding physiologically acceptable salts including trifluoroacetates, specifically the pharmaceutically acceptable salts.
  • the compounds of the formula I which have one or more basic, i.e. protonatable, groups or comprise one or more basic heterocyclic rings, can also be used in the form of their physiologically tolerated acid addition salts with inorganic or organic acids, for example as hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates etc. Salts can be obtained from compounds of the formula I by conventional processes, for example by combining with an acid in a solvent or dispersant or else by anion exchange from other salts.
  • the compounds of the formula I may also be
  • alkali metal salts in one embodiment as sodium or potassium salts, or as ammonium salts, for example as salts with ammonia or organic amines or amino acids.
  • A phenyl substituted a residue selected from CI, NC-, or CF 3 , for example in the meta- position;
  • R1 R10-C(O)-
  • R2 OH
  • R3, R4, R5, R6 and R8 H;
  • R7, R9 are independently selected from F and CI;
  • R10 methyl, ethyl, isopropyl, cyclopropyl
  • the compounds of the formula I may exist in stereoisomeric forms.
  • the centers of asymmetry which are present may independently of one another have the S configuration or the R configuration.
  • the invention includes all possible
  • stereoisomers for example enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, for example enantiomers and/or diastereomers, in any ratios.
  • the invention thus includes for example enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in various ratios or in the form of racemates.
  • Individual stereoisomers can be prepared as desired by fractionating a mixture by conventional methods or for example by stereoselective synthesis.
  • residues R1 , R2, R3, R6, R7, R8, R9 and A have the same meaning as in compounds of the formula I, provided that no specific definition of the respective residue is mentioned.
  • residues R4 and R5 are hydrogen atoms. However, these reactions can be carried out analogously with compounds, wherein R4 and R5 have an above- mentioned meaning other than hydrogen.
  • acyl chlorides can alternatively be prepared by standard procedures from the corresponding acids e.g. by reaction with thionyl chloride in the presence of catalytic amounts of DMF (see for example Dalisay, D. S.; Quach, T.; Nicholas, G. N.;
  • the diketones 2 are obtained and can be subjected to ring-closure with hydrazine hydrate to give the corresponding diverse 4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridine intermediates 3.
  • the second intermediates needed in the synthesis of the described TASK-1 blockers can be obtained by epoxidation of various substituted indenes 5 as shown in Scheme 2 by following a reaction sequence as published before (WO 2010/025856, particularly on page 1 14-1 17).
  • the indenes can be either purchased commercially or synthesized in a short sequence starting from indan-1 -ones. Thus reduction with sodium borohydride yields in the corresponding indan-1 -ols 4. After elimination of water for example by heating in toluene in the presence of a catalytic amount of para- toluene sulfonic acid monohydrate gives the corresponding indenes 5.
  • epoxidation can be performed in an enantioselective manner according to reaction steps A or B in Scheme 2 by using the Jacobsen catalyst which is commercially available (Larrow, Jay F.; Roberts, Ed; Verhoeven, Thomas R.; Ryan, Ken M.;
  • reaction step A a (S,S)-Jacobsen catalyst
  • reaction B a (R,R)-Jacobsen catalyst is used together with 4-(3-phenylpropyl)pyridine N-oxide.
  • racemic epoxides can be obtained by using meta-chloroperbenzoic acid as reagent (reaction step C).
  • reaction step D Another approach is the 2 step oxidation with N-bromosuccinimide followed by elimination of HBr with NaOH (reaction step D).
  • 2-alkyl-1 H-indenes 9 are obtained in the presence of a catalytic amount of para-toluene sulfonic acid monohydrate which can be submitted to diverse epoxidation procedures as described above to give epoxides 10.
  • epoxides 10 for the preparation of racemic epoxides for example the addition of meta-chloroperbenzoic acid as reagent is suitable.
  • R2 is H or a (Ci-C6)-alkyl, (Ci-C6)-alkyloxy, (Ci-C6)-alkyl-C(O)O- group.
  • Compound 4' and 8', wherein R2 is a (Ci-C6)-alkyl, (Ci-C6)-alkyloxy or (Ci-C6)-alkyl-C(O)O- group can be prepared analogously to Scheme 2 and 3.
  • the group R1 can be varied synthetically as shown in Scheme 8.
  • the N-acetyl group can be cleaved by heating an acidic aqueous solution of compounds 11/12, for example in a mixture of ethanol and 2N aqueous HCI.
  • the corresponding amines 13 can be modified in a variety of ways, for example by acylation as shown in Scheme 9 in an inert solvent like CH2CI2 and in the presence of a base like triethylamine.
  • the N-acylated compounds 14 have been found to be potent TASK-1 blockers.
  • R2 OH
  • diacylated compounds 15 can also be isolated as side-product which have also been found to be TASK-1 blockers. In cases where A contains a CN group (cyano group, NC-) this group can be partially converted to a carboxamide group. These side products can easily be separated.
  • the group R1 can be varied additionally and converted to novel urethane compounds 17 as shown in Scheme 1 1 , for example by reaction of compounds 13 with
  • alkylchloroformates in an inert solvent like CH2CI2 in the presence of a base like triethylamine, wherein the residue R is a (Ci-Ce)-alkyl group.
  • Scheme 1 1 The group R1 can also be varied to novel amines 18 as shown in Scheme 12, for example by reaction of compounds 13 with unsubstituted or substituted alkyl halogenides in an inert solvent like CH 3 CN or DMF in the presence of a base like triethylamine.
  • Suitable alkyl halogenides are of the formula R1 -Hal, wherein R1 is selected from the residues R 11 -(Ci-C6)-alkyl-.
  • Other methods can be used as reductive amination with aldehydes (for a review see E. W. Baxter and A. B. Reitz, Organic Reactions, 1 , 59, 2002).
  • Alkyl groups R can be introduced in compounds starting from compounds 11712' where one of the groups R5, R6, R7, R8 is a halogen for example bromine according to Scheme 13.
  • the residue R1 of compounds 11' and 12' is for example R10-C(O)-, specifically CH 3 -C(O)-.
  • tetralkyltin SnR , wherein R is equal to a (Ci-Ce)-alkyl group
  • a catalyst for example tetrakis(triphenylphosphine)palladium(0)
  • Cyclopropyl or aryl groups can be introduced with the Suzuki reaction (N. Miyaura, A. Suzuki: J. Chem. Soc, Chem. Commun. 1979, S. 866-867) in compounds starting from compounds 11712' where one of the groups R5, R6, R7, R8 is a halogen for example bromine according to Scheme 14.
  • the residue R1 of compounds 11' and 12' is for example R10-C(O)-, specifically CH 3 -C(O)-.
  • novel cyclopropyl substituted compounds 20 can be obtained which are active TASK-1 blockers.
  • R1 can also be varied to novel sulfonamides 23 as shown in Scheme 16, for example by reaction of compounds 13 with alkylsulfonylchloride (R-SO2CI, wherein R is equal to a (Ci-C6)-alkyl group) in an inert solvent like CH2CI2 in the presence of a base for example triethylamine.
  • R-SO2CI alkylsulfonylchloride
  • the group R1 can also be varied to novel ureas 22/22', wherein R12 in 22' is equal to a (Ci-C6)-alkyl group, as shown in Scheme 17-18, for example by reaction of compounds 13 with isocyanates or by step-wise reaction with phosgene followed by an amine (see for example Journal of Medicinal Chemistry (2010), 53(24), 8468-8484 for a similar reaction).
  • the compounds of the formula I and/or their pharmaceutically compatible salts are suitable for the prevention and treatment of disorders which are caused by activation or by an activated TASK-1 , and also of disorders in which have TASK-1 - related damages appear secondary to another, primary cause.
  • the compounds of the formula I and/or physiologically compatible salts thereof can also be used for the treatment and prevention of disorders where TASK-1 requires only partial inhibition, for example by using a lower dosage.
  • the compounds of the formula I and/or their pharmaceutically acceptable salts can be employed to produce medicaments with a TASK-1 channel-blocking effect for the therapy and prophylaxis of TASK-1 channel-mediated diseases.
  • the compounds of the formula I and/or their pharmaceutically acceptable salts can further be used for the therapy or prophylaxis of cardiac arrhythmias, e.g. of arrhythmias that respond to the changes in the shape of the action potential, mainly a prolongation of the action potential, which is induced by TASK-1 blockade.
  • the compounds of the formula I and/or their pharmaceutically acceptable salts can be employed for terminating existent atrial fibrillation or flutter to restore the sinus rhythm (cardioversion).
  • the compounds reduce the susceptibility for a new development of atrial fibrillation events, thus the compounds are suitable for prophylactic treatment by maintenance of sinus rhythm (rhythm control).
  • the substances are devoid of a ventricular proarrhythmic risk (prolongation of the QT- interval and Torsades de pointe arrhythmias).
  • the compounds of the formula I and/or their pharmaceutically acceptable salts can be employed for producing a medicament for the treatment and/or prevention of arrhythmias, for example atrial trachyarrhythmias, atrial fibrillation and atrial flutter
  • the compounds of the formula I and/or their pharmaceutically acceptable salts are further suitable for producing a medicament for the therapy or prophylaxis of sleep- related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle- related respiratory disorders, respiratory disorders after long-term mechanical ventilation (weaning), respiratory disorders during adaptation in high mountains, acute and for respiratory disorders, chronic lung disorders with hypoxia and hypercapnia, chronic obstructive pulmonary disease (COPD) and obesity
  • the compounds of the formula I and/or their pharmaceutically acceptable salts are further suitable as a respiratory stimulant for the prevention and treatment of respiratory depression associated with anesthesia or procedural sedations for small interventions or for diagnostic purposes, for the treatment and prevention of respiratory depression by opioids in chronic pain treatment e.g. in cancer or palliative care or procedural sedations and/or for weaning from longterm mechanical ventilation.
  • the compounds of the formula I and/or their pharmaceutically acceptable salts are further suitable for the treatment and/or prevention of multiple scelrosis and inflammatory and degenerative disorders of the central nervous system.
  • a further embodiment of the present invention is a pharmaceutical preparation, or a pharmaceutical composition, comprising an effective amount of a compound of the formula I and/or of its pharmaceutically acceptable salts, together with
  • the pharmaceutical preparations usually comprise from 0.1 to 90 percent by weight of the compounds of the formula I and/or their pharmaceutically acceptable salts.
  • the pharmaceutical preparations can be produced in a manner known per se. For this purpose, the compounds of the formula I and/or their pharmaceutically acceptable salts are converted together with one or more solid or liquid pharmaceutical vehicles and/or excipients and, if desired, in combination with other pharmaceutical active ingredients into a suitable dosage form, which can then be used as pharmaceutical in human medicine or veterinary medicine.
  • pharmaceutically acceptable salts can moreover be administered for example orally, intravenously, intramuscular, subcutaneously, nasally, topically, pharyngeally or by inhalation, and the preferred administration depends on the individual case, for example on the particular manifestation of the disorder.
  • the compounds of the formula I can moreover be used alone or together with pharmaceutical excipients, in particular both in veterinary and in human medicine.
  • the pharmaceuticals comprise active ingredients of the formula I and/or their pharmaceutically acceptable salts generally in an amount of from 0.01 mg to 1 g per dose unit.
  • excipients are suitable for the desired pharmaceutical formulation.
  • solvents gel formers, suppository bases, tablet excipients and other active substance carriers it is possible to use for example antioxidants, dispersants, emulsifiers, antifoams, masking flavors, preservatives, solubilizers, agents for achieving a depot effect, buffer substances or colorants.
  • the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable presentations such as tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily solutions.
  • inert carriers examples include gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can take place both as dry and as wet granules.
  • Suitable as oily carriers or as solvents are, for example, vegetable or animal oils such as sunflower oil or fish liver oil.
  • Suitable solvents for aqueous or alcoholic solutions are, for example, water, ethanol or sugar solutions or mixtures thereof.
  • further excipients, also for other administration forms are polyethylene glycols and polypropylene glycols.
  • the active compound for subcutaneous, intramuscular or intravenous administration, the active
  • the compounds of the formula I and/or their pharmaceutically acceptable salts may also be lyophilized and the resulting lyophilizates be used, for example, for producing products for injection or infusion.
  • suitable solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else mixtures of the various solvents mentioned.
  • Suitable as pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of the formula I or their pharmaceutically acceptable salts in a pharmaceutically acceptable solvent, such as ethanol or water, or a mixture of such solvents.
  • the formulation may if required also comprise other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas.
  • Such a preparation comprises the active ingredient normally in a concentration of about 0.1 to 10, in particular of about 0.3 to 3 percent by weight.
  • the dosage of the active ingredient to be administered or of the pharmaceutically acceptable salts thereof depends on the individual case and should be adapted to the circumstances of the individual case as usual for an optimal effect.
  • the daily dose of a compound of the formula I and/or its pharmaceutically acceptable salts for a patient weighing about 75 kg is normally at least 0.001 mg/kg to 100 mg/kg of body weight, for example 0.01 mg/kg to 20 mg/kg. Even higher dosages may also be necessary for acute episodes of the disease, for example in an intensive care unit. Up to 800 mg per day may be necessary.
  • the dose may be in the form of a single dose or be divided into a plurality, for example two, three or four, single doses.
  • intravenous infusion may also be advantageous, especially in the treatment of acute cases of cardiac arrhythmias, for example in an intensive care unit.
  • Example 1 1 -(4-Morpholin-4-yl-3,6-dihydro-2H-pyridin-1 -yl)-ethanone (1 )
  • step 1 A mixture of morpholine (67.85 g, 0.779 mol), 1 - acetyl-4-piperidone (99.95 g, 0.708 mol) and para-toluenesulfonic acid monohydrate (0.366 g, 2.1 mmol) in toluene (300 ml) was heated in a Dean-Stark trap apparatus for 16 h at reflux. Solvents were evaporated in vacuo to give 149 g of 1 -(4-morpholin- 4-yl-3,6-dihydro-2H-pyridin-1 -yl)-ethanone (1 ) which was used in the next step without any further purification.
  • steps 2-3 To a solution of 1 -(4-morpholin-4-yl-3,6-dihydro- 2H-pyridin-1 -yl)-ethanone (1 ) (6.35 g, 30.2 mmol) in dry dichloromethane (30 ml) at 0°C was added triethylamine (3.056 g, 30.2 mmol) and after stirring the solution at 0°C for 10 min, 3-cyanobenzochloride (5 g, 30.2 mmol) was added. The mixture was stirred for 45 min at 0°C then the mixture was allowed to warm to room temperature and stirred overnight. 5% aqueous HCI was added and the mixture was stirred for 2 h.
  • step 1 To a solution of 4-Bromo-6-fluoro-indan-1 -one (10.0 g, 43.7 mmol) in ethanol (183 ml) at 0°C NaBH 4 (3.67 g, 97.0 mmol) was added in portions and then the mixture was stirred at room temperature for 18 h. After evaporation of solvents in vacuo, water was added to the residue, the solution was extracted 3 times with ethyl acetate, then 2N aqueous HCI was added and the combined organic layers were washed with saturated aq. NaHCO3 and water. After drying over Na 2 SO 4 and filtration, solvents were evaporated in vacuo to give 10.0 g of 4-Bromo-6-fluoro-indan-1 -ol (4a) which was used immediately in the next step without purification.
  • step I / II
  • the compound was characterized by 1 H-NMR spectroscopy as follows:
  • step IV To a solution of 5,6-dichloro-1 H-indene (5f) (1 .28 g, 6.92 mmol), which was obtained according to Scheme 2 by following a reaction sequence according to synthesis of (5a), in dimethylsulfoxide (6.5 ml) and water (0.16 ml) N-bromosuccinimide (2.44 g, 13.7 mmol) was added at 10°C and the mixture was stirred at 25 °C for 1 h. The mixture was poured on water, stirred for 30 min and the solid material was filtered off.
  • the crude product was purified by silica gel chromatography (eluting with 0 to 50 % ethyl acetate in heptane) to give 1 .46 g of 2-bromo-5,6-dichloro-indan-1 -ol which was immediately dissolved in tetrahydrofuran (35 ml). Finely powdered NaOH (1 .37 g, 34.2 mmol) was added and the mixture was stirred at 25°C for 2 h. The mixture was filtered through a short pad of celite and washed with a small amount of ethyl acetate.
  • step III To a solution of 5,6-dichloro-1 H-indene (5g) (4.35 g, 23.5 mmol), which was obtained according to Scheme 2 by following a reaction sequence according to synthesis of (5a), in CH2CI2 (80 ml) was added meta- chloroperbenzoic acid (6.28 g, 25.5 mmol) and the mixture was stirred at 25 °C for 16 h. The mixture was diluted with CH2CI2, the solid filtered off. The solution was washed with aqueous saturated Na 2 S 2 O3 solution, with aqueous saturated NaHCO3 and water, dried over Na 2 SO 4 , filtrated and the solution was evaporated to dryness.
  • step 1 to a solution of 4,6-difluoro-indan-1 -one (5.0 g, 29.8 mmol) in dry tetrahydrofuran (100 ml) at -78°C a 2M solution of
  • step 2 to a solution 4,6-Difluoro-2-methyl-indan-1 -one (7a) (1 .27 g, 6.97 mmol) in ethanol (30 ml) NaBH 4 (0.26 g, 6.97 mmol) was added in portions at 0°C and then the mixture was stirred at room temperature for 18 h. After evaporation of solvents in vacuo, water was added to the residue, the solution was extracted 3 times with ethyl acetate, then 2N aqueous HCI was added and the combined organic layers were washed with saturated aq. NaHCO3 and water. After drying over Na 2 SO 4 and filtration, solvents were evaporated in vacuo to give 650 mg 4,6-Difluoro-2-methyl-indan-1 -ol (8a) which was used immediately in the next step without purification.
  • step 3 A mixture of 4,6-Difluoro-2-methyl-indan-1 -ol (8a) (0.65 g, 3.53 mmol) and para-toluene sulfonic acid monohydrate (30 mg, 0.18 mmol) in toluene was heated at reflux for 1 h. The solution was washed with aqueous saturated NaHCO3 and brine, dryied over MgSO 4 and solvents evaporated. The crude product was purified by silica gel chromatography (eluting with 0% to 100 % ethyl acetate in heptane to give 0.50 g of 5,7-Difluoro-2-methyl-1 H-indene (9a) which was used immediately in the next step.
  • Example 10 Racemic (1 aS,6aR)-3,5-Difluoro-6a-methyl-6,6a-dihydro-1 aH-1 -oxa- cyclopropa[a]indene (10a)
  • step 4 To a solution of 5,7-Difluoro-2-methyl-1 H-indene (9a) (0.44 g, 2.65 mmol) in CH 2 CI 2 (3 ml) meta-chloroperbenzoic acid (707 mg, 2.87 mmol) was added and the mixture was stirred at 25 °C for 16 h. The mixture was diluted with CH 2 CI 2 and the solid filtered off.
  • Example 1 1 1 -[1 -((1 R,2R)-4,6-Difluoro-2-hydroxy-indan-1 -yl)-3-(3-trifluoromethoxy-ph 1 ,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl]-ethanone (1 1 a)
  • the mixture was stirred at -70°C for 15 min and then a second portion of the methanesulfonyl/tetrahydrofuran solution above was added (100 ⁇ ). The mixture was stirred at -70°C for 15 min and then a third portion of the methanesulfonyl/tetrahydrofuran solution above was added (50 ⁇ ). The mixture was stirred at -70°C for 3 min, quenched with aqueous NaHCO3 and extracted 3 times with CH2CI2.
  • TASK-1 channels were expressed in Xenopus oocytes.
  • oocytes were isolated from Xenopus laevis and defoliculated.
  • TASK- 1 -encoding RNA synthesized in vitro was injected into oocytes.
  • TASK-1 currents were measured by two-microelectrode voltage clamp. Data were acquired and analyzed using a TEC-10cx amplifier (NPI Electronic, Tamm, Germany) connected to an ITC-16 interface (Instrutech Corp., Long Island, USA) and Pulse software (HEKA Elektronik, Lambrecht, Germany).
  • Oocytes were clamped to -90 mV and TASK-1 mediated currents were measured during 500 ms voltage pulses to 40 mV. Oocytes were continuously superfused with ND96 buffer containing: NaCI 96 mM, KCI 2 mM, CaCI 2 1.8 mM, MgCI 2 1 mM, HEPES 5 mM (pH adjusted to 7.4 with NaOH). All experiments were performed at room temperature.
  • Example IC50 Example IC50
  • Example IC50 Example IC50
  • Example IC50 Example IC50
  • S2 extra-stimulus
  • the refractory period values are stated in percent of the basal values 15 minutes after injection. Mean values for the refractory periods are shown from three rates (150, 200 and 250/min).
  • the inhibitory values for the inhibition of episodes of arrhythmias refer to 3 measurements (3 timepoints) before administration vs. 3 measurements during the first hour after administration of the compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des 4,5,6,7-tétrahydro-1 H-pyrazolo[4,3-c]pyridines substituées de formule (I), leur utilisation comme médicament et des préparations pharmaceutiques les contenant. Les composés de formule I agissent sur le canal potassique TASK-1. Les composés sont appropriés pour traiter ou prévenir les arythmies auriculaires, par exemple la fibrillation auriculaire (FA) ou le flutter auriculaire.
PCT/EP2012/067654 2011-09-12 2012-09-10 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant WO2013037736A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2014002968A MX2014002968A (es) 2011-09-12 2012-09-10 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
BR112014005583A BR112014005583A2 (pt) 2011-09-12 2012-09-10 4,5,6,7-tetra-hidro-1h-pirazolo[4,3-c]piridinas substituídas com indanila, seu uso como medicamento, e preparações farmacêuticas que as contêm
EA201490621A EA023648B1 (ru) 2011-09-12 2012-09-10 ИНДАНИЛЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306129.5 2011-09-12
EP11306129 2011-09-12

Publications (1)

Publication Number Publication Date
WO2013037736A1 true WO2013037736A1 (fr) 2013-03-21

Family

ID=46829768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/067654 WO2013037736A1 (fr) 2011-09-12 2012-09-10 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant

Country Status (4)

Country Link
BR (1) BR112014005583A2 (fr)
EA (1) EA023648B1 (fr)
MX (1) MX2014002968A (fr)
WO (1) WO2013037736A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097671A1 (fr) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation
US10759794B2 (en) 2015-12-10 2020-09-01 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
US11098063B2 (en) 2017-06-14 2021-08-24 Bayer Aktiengesellschaft Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086422A2 (fr) 1982-02-17 1983-08-24 GRUPPO LEPETIT S.p.A. Pyrazolo (4,3-c)pyridines à activité pharmacologique
WO2005016965A1 (fr) 2003-07-18 2005-02-24 Bayer Healthcare Ag Modulateurs des canaux potassium twik-1, task-1, girk1, sk2 ou pcn1 pour le traitement des arythmies, des coronaropathies ou de l'hypertension
WO2006136304A1 (fr) 2005-06-22 2006-12-28 Sanofi-Aventis Hétérocycles substitués, leur utilisation comme médicament et préparations pharmaceutiques les comprenant
WO2007124849A2 (fr) 2006-04-27 2007-11-08 Sanofi-Aventis Deutschland Gmbh Inhibiteurs du canal ionique task-1 et task-3
WO2010025856A1 (fr) 2008-09-02 2010-03-11 Sanofi-Aventis Aminoindanes substitués, leurs analogues, et leur utilisation pharmaceutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086422A2 (fr) 1982-02-17 1983-08-24 GRUPPO LEPETIT S.p.A. Pyrazolo (4,3-c)pyridines à activité pharmacologique
WO2005016965A1 (fr) 2003-07-18 2005-02-24 Bayer Healthcare Ag Modulateurs des canaux potassium twik-1, task-1, girk1, sk2 ou pcn1 pour le traitement des arythmies, des coronaropathies ou de l'hypertension
WO2006136304A1 (fr) 2005-06-22 2006-12-28 Sanofi-Aventis Hétérocycles substitués, leur utilisation comme médicament et préparations pharmaceutiques les comprenant
WO2007124849A2 (fr) 2006-04-27 2007-11-08 Sanofi-Aventis Deutschland Gmbh Inhibiteurs du canal ionique task-1 et task-3
WO2010025856A1 (fr) 2008-09-02 2010-03-11 Sanofi-Aventis Aminoindanes substitués, leurs analogues, et leur utilisation pharmaceutique

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
BASIC RES CARDIOL., vol. 106, no. L, January 2011 (2011-01-01), pages 75 - 87
BASIC. RES. CARDIOL., vol. 98, 2003, pages 137 - 148
BAYLISS D.A.; TALLEY E.M.; SIROIS J.E.; LEI Q.: "TASK-1 is a highly modulated pH-sensitive 'leak' K+ channel expressed in brainstem respiratory neurons", RESPIRATION PHYSIOLOGY, 2001, pages 159 - 174
BERG A.P.; TALLEY E.M.; MANGER J.P.; BAYLISS D.A.: "Motoneurons express Heteromeric TWIK- related acid-sensitive K+ (TASK) Channels containing TASK-1 (KCNK3) and TASK-3 (KCNK9) subunits", J. NEUROSCIENCE, 2004, pages 6693 - 6702
BITTNER STEFAN; MEUTH SVEN G; GOBEL KERSTIN; MELZER NICO; HERRMANN ALEXANDER M; SIMON OLE J; WEISHAUPT ANDREAS; BUDDE THOMAS; BAYL, BRAIN : A JOURNAL OF NEUROLOGY, vol. 132, 2009, pages 2501 - 16
BRUNDEL B.J.J.M. ET AL., JACC, vol. 37, 2001, pages 926 - 932
BUCKLER K.J.; WILLIAMS B.A.; HONORE E.: "An oxygen-, acid- and anaesthetic-sensitive TASK-like background potassium channel in rat arterial chemoreceptor cells", J. PHYSIOL., 2000, pages 135 - 142
BULL. CHEM. SOC. JAPAN, vol. 40, 1967, pages 2380 - 2382
COETZEE W.J. ET AL.: "Molecular diversity of K+ channels", ANN. NEW YORK ACAD. SCI., 1999, pages 233 - 285
COTTEN J.F.; KESHAVAPRASAD B.; LASTER M.J.; EGER E.I.; YOST C.S.: "The Ventilatory Stimulant Doxapram Inhibits TASK Tandem Pore (K2P) Potassium Channel Function but Does Not Affect Minimum Alveolar Anesthetic Concentration", ANESTH. ANALG., 2006, pages 779 - 785
D. M. RODEN, AM. J. CARDIOL., vol. 72, 1993, pages 44B - 49B
D.A. BAYLISS; P. BARRETT, TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 29, no. 11, 2008, pages 566 - 575
DALISAY, D. S.; QUACH, T.; NICHOLAS, G. N.; MOLINSKI, T. F., ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 48, 2009, pages 4367 - 4371
DUPRAT F.; LESAGE F.; FINK M.; REYES R.; HEURTEAUX C.; LAZDUNSKI M.: "TASK, a human background K+ channel to sense external pH variations near physiological pH", EMBO J., 1997, pages 5464 - 5471
E. W. BAXTER; A. B. REITZ, ORGANIC REACTIONS, vol. 1, 2002, pages 59
ELLINGHAUS P. ET AL., J. THORACIC CARDIOVASCULAR SURGERY, vol. 129, 2005, pages 1383 - 1390
EUROPEAN JOURNAL OF PHYSIOLOGY, vol. 450, 2005, pages 201 - 208
JOURNAL OF CLINICAL INVEST., vol. 121, no. 8, 2011, pages 2955 - 2968
JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 24, 2010, pages 8468 - 8484
JOURNAL OF MOLECULAR MEDICINE, 2004, pages 308 - 316
JOURNAL OF NEUROSCIENCE, vol. 25, no. 49, 2005, pages 11455 - 11467
KNOBLOCH ET AL., NAUNYN-SCHMIEDBERG'S ARCH. PHARMACOL., vol. 366, 2002, pages 482 - 487
LARROW, JAY F.; ROBERTS, ED; VERHOEVEN, THOMAS R.; RYAN, KEN M.; SENANAYAKE, CHRIS H.; REIDER, PAUL J.; JACOBSEN, ERIC N., ORGANIC SYNTHESES, 1999, pages 76
LAURITZEN I.; ZANZOURI M.; HONORE E.; DUPRAT F.; EHRENGRUBER M.U.; LAZDUNSKI M.; PATEL A.J.: "K+- dependent cerebellar granule neuron apoptosis - Role of Task leak K+ channels", J. BIOL. CHEM., 2003, pages 32068 - 32076
MACDONALD, SIMON J. F.; MCKENZIE, THOMAS C.; HASSEN, WESLEY D., JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, 1987, pages 1528 - 30
MAHAPATRA, TRIDIB; JANA, NANDAN; NANDA, S, TETRAHEDRON: ASYMMETRY, vol. 19, no. 10, 2008, pages 1224 - 1232
MAINGRET F.; PATEL A.J.; LAZDUNSKI M.; HONORE E.: "The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1", EMBO J., 2001, pages 47 - 54
MEDHURST A.D.; RENNIE G.; CHAPMAN C.G.; MEADOWS H.; DUCKWORTH M.D.; KELSELL R.E.; GLOBER I.I.; PANGALOS M.N.: "Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery", MOL. BRAIN RES., 2001, pages 101 - 114
N. MIYAURA; A. SUZUKI, J. CHEM. SOC., CHEM. COMMUN., 1979, pages 866 - 867
PATEL A.J.; HONORE E.: "Properties and modulation of mammalian 2P domain K+ channels", TRENDS NEUROSCI., 2001, pages 339 - 346
PATEL A.J.; HONORE E.; LESAGE F.; FINK M.; ROMEY G.; LAZDUNSKI M.: "Inhalational anesthetics activate two-pore-domain background K+ channels", NATURE, 1999, pages 422 - 426
PATEL A.J.; LAZDUNSKI M.: "The 2P-domain K+ channels: role in apoptosis and tumorigenesis", PFLUGERS ARCH., 2004, pages 261 - 273
PEUKERT, S.; BRENDEL, J.; PIRARD, B.; BRUEGGEMANN, A.; BELOW, P.; KLEEMANN, H.-W.; HEMMERLE, H.; SCHMIDT, W.: "Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 4, 2003, pages 486 - 498
PUTZKE C; WEMHONER K; SACHSE FB; RINNE S; SCHLICHTH6RL G; LI XT; JAE L; ECKHARDT I; WISCHMEYER E; WULF H, CARDIOVASCULAR RESEARCH, vol. 75, 2007, pages 59 - 68
STREIT, A. K.; NETTER, M. F.; KEMPF, F.; WALECKI, M.; RINNE, S.; BOLLEPALLI, M. K.; PREISIG-MUELLER, R.; RENIGUNTA, V.; DAUT, J.;: "A Specific Two-pore Domain Potassium Channel Blocker Defines the Structure of the TASK-1 Open Pore", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 16, 2011, pages 13977 - 13984
T. J. COLATSKY ET AL., DRUG DEV. RES., vol. 19, 1990, pages 129 - 140

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097671A1 (fr) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation
CN108699084A (zh) * 2015-12-10 2018-10-23 拜耳制药股份公司 取代全氢吡咯并[3,4-c]吡咯衍生物及其用途
JP2018538296A (ja) * 2015-12-10 2018-12-27 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用
US10414765B2 (en) 2015-12-10 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
US10759794B2 (en) 2015-12-10 2020-09-01 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
US11098063B2 (en) 2017-06-14 2021-08-24 Bayer Aktiengesellschaft Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

Also Published As

Publication number Publication date
MX2014002968A (es) 2014-07-09
EA201490621A1 (ru) 2014-08-29
BR112014005583A2 (pt) 2017-03-21
EA023648B1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2011376721B2 (en) Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
US9884860B2 (en) Fused pyrroledicarboxamides and their use as pharmaceuticals
WO2013037914A1 (fr) 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées, leur utilisation comme médicament, et préparations pharmaceutiques les contenant
AU2016323297A1 (en) Hepatitis B core protein modulators
EP2878594B1 (fr) Composé de difluorométhylène
EP2951179B1 (fr) Derives de spiro-quinazolinone utiles dans le traitement de maladies et conditions neurologiques
JP6893516B2 (ja) ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
EP3402783B1 (fr) Derives de 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane
WO2013037736A1 (fr) 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant
AU2011376747B2 (en) Indanyl-substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
US20220153735A1 (en) Orai Channel Inhibitors
JP2024524765A (ja) アミド化合物とその応用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756734

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/002968

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 201490621

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014005583

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 12756734

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112014005583

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140311